Vaccinations for the Older Adult

Clinics in Geriatric Medicine

Volumn 32, Issue 3, 2016, Pages 609-625

  Gnanasekaran, Gowrishankar ^a   Biedenbender, Rex ^b   Davidson, Harley Edward ^c   Gravenstein, Stefan ^a,d  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b Jencare Neighborhood Medical Center   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

Conjugate; Diphtheria; Immune senescence; Influenza; Pertussis; Pneumococcus; Tetanus; Vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; VACCINE;

AGE; ALCOHOLISM; CHRONIC DISEASE; DIABETES MELLITUS; DIPHTHERIA; DRUG APPROVAL; DRUG SAFETY; EPIDEMIOLOGICAL DATA; HEALTH CARE PERSONNEL; HEART DISEASE; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; INFLUENZA; LIVER DISEASE; LUNG DISEASE; MASS IMMUNIZATION; PERTUSSIS; PNEUMONIA; REVIEW; RISK FACTOR; TETANUS; TREATMENT INDICATION; AGED; INFECTION CONTROL; PROCEDURES; VACCINATION;

AGED; HUMANS; INFECTION CONTROL; VACCINATION; VACCINES, CONJUGATE;

EID: 84990207916     PISSN: 07490690     EISSN: 18798853     Source Type: Journal    
DOI: 10.1016/j.cger.2016.03.001     Document Type: Review

References (46)

1. 1 Kale, S.S., Ahuja, N., Yende, S., et al. Newman, A.B., Cauley, J.A., (eds.) The epidemiology of aging, 2012, Springer, Dordecht (Netherlands), 237–253.
2. 2 Taub, D.D., Longo, D.L., Insights into thymic aging and regeneration. Immunol Rev 205 (2005), 72–93.
3. 3 Lambert, N.D., Ovsyannikova, I.G., Pankratz, V.S., et al. Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach. Expert Rev Vaccines 11 (2012), 985–994.
4. 4 McLaughlin, J.M., McGinnis, J.J., Tan, L., et al. Estimated human and economic burden of four major adult vaccine-preventable diseases in the United States, 2013. J Prim Prev 36:4 (2015), 259–273.
5. 5 Centers for Disease Control and Prevention, Epidemiology and prevention of vaccine-preventable diseases. Hamborsky, J., Kroger, A., Wolfe, S., (eds.), 13th edition, 2015, Public Health Foundation, Washington, DC, 12.
6. 6 Thompson, W.W., Comanor, L., Shay, D.K., Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease. J Infect Dis 194:Suppl 2 (2006), S82–S91.
7. 7 Smeeth, L., Thomas, S.L., Hall, A.J., et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 351 (2004), 2611–2618.
8. 8 Nichol, K.L., Nordin, J., Mullooly, J., et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 348 (2003), 1322–1332.
9. 9 Phrommintikul, A., Kuanprasert, S., Wongcharoen, W., et al. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J 32 (2011), 1730–1735.
10. 10 Clar, C., Oseni, Z., Flowers, N., et al. Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev(5), 2015 CD005050.
11. 11 Jefferson, T., Di Pietrantonj, C., Al-Ansary, L.A., et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev(2), 2010 CD004876.
12. 12 Goodwin, K., Viboud, C., Simonsen, L., Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24 (2006), 1159–1169.
13. 13 Keitel, W.A., Atmar, R.L., Cate, T.R., et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 166 (2006), 1121–1127.
14. 14 Nace, D.A., Len, C.J., Ross, T.M., et al. Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities. J Infect Dis 211 (2015), 1915–1924.
15. 15 DiazGranados, C.A., Dunning, A.J., Jordanov, E., et al. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009–2010 season. Vaccine 31 (2013), 861–866.
16. 16 DiazGranados, C.A., Dunning, A.J., Kimmel, M., et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 371 (2014), 635–645.
17. 17 Izurieta, H.S., Thadani, N., Shay, D.K., et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis 15 (2015), 293–300.
18. 18 ClinicalTrials.gov Registration: NCT01815268.
19. 19 FLUAD [package insert]. Cambridge, MA: Novartis Vaccines and Diagnostics, Inc.; 2015.
20. 20 Della Cioppa, G., Nicolay, U., Lindert, K., et al. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 ((R)) adjuvant: results from a dose-finding clinical trial in older adults. Human Vaccines & Immunotherapeutics 8 (2012), 216–227.
21. 21 Centers for Disease Control and Prevention. Influenza (flu). 2015. Available at: www.cdc.gov/flu/protect/vaccine/vaccines.htm. Accessed September 18, 2015.
22. 22 Osterholm, M.T., Kelley, N.S., Sommer, A., et al. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12 (2012), 36–44.
23. 23 Grohskopf, L.A., Sokolow, L.Z., Olsen, S.J., et al. Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2015-16 influenza season. MMWR Morb Mortal Wkly Rep 64 (2015), 818–825.
24. 24 Centers for Disease Control and Prevention. Adult immunization schedules. United States, 2015. Available at: http://www.cdc.gov/vaccines/schedules/hcp/adult.html. Accessed September 15, 2015.
25. 25 Office of Disease Prevention and Health Promotion. Increase the percentage of health care personnel who are vaccinated annually against seasonal influenza. 2013. Available at: https://www.healthypeople.gov/node/6361/data_details#revision_history_header. Accessed October 21, 2015.
26. 26 Black, C.L., Yue, X., Ball, S.W., et al. Influenza vaccination coverage among health care personnel – United States, 2013-14 influenza season. MMWR Morb Mortal Wkly Rep 63 (2014), 805–811.
27. 27 Ahmed, F., Lindley, M.C., Allred, N., et al. Effect of influenza vaccination of healthcare personnel on morbidity and mortality among patients: systematic review and grading of evidence. Clin Infect Dis 58 (2014), 50–57.
28. 28 Griffin, M.R., Influenza vaccination of healthcare workers: making the grade for action. Clin Infect Dis 58 (2014), 58–60.
29. 29 Potter, J., Stott, D.J., Roberts, M.A., et al. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis 175 (1997), 1–6.
30. 30 National Vaccine Advisory Committee, Strategies to achieve the Healthy People 2020 annual influenza vaccine coverage goal for health-care personnel: recommendations from the National Vaccine Advisory Committee. Public Health Rep 128 (2013), 7–25.
31. 31 Centers for Disease Control and Prevention. National Center for Health Statistics. Health, United States, 2009: with special feature on medical technology. Hyattsville (MD): Department of Health and Human Services; 2010.
32. 32 World Health Organization, 23-valent pneumococcal polysaccharide vaccine: WHO position paper. Wkly Epidemiol Rec 83 (2008), 373–384.
33. 33 Curcio, D., Cane, A., Isturiz, R., Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence. Int J Infect Dis 37 (2015), 30–35.
34. 34 Moberley, S., Holden, J., Tatham, D.P., et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev(1), 2013 CD000422.
35. 35 Musher, D.M., Editorial commentary: should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults?. Clin Infect Dis 55 (2012), 265–267.
36. 36 Williams, W.W., Lu, P.J., O'Halloran, A., et al. Vaccination coverage among adults, excluding influenza vaccination – United States, 2013. MMWR Morb Mortal Wkly Rep 64 (2015), 95–102.
37. 37 Pletz, M.W., Maus, U., Krug, N., et al. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents 32 (2008), 199–206.
38. 38 Centers for Disease Control and Prevention, Manual for the surveillance of vaccine-preventable diseases. 2012, Centers for Disease Control and Prevention, Atlanta (GA).
39. 39 Moore, M.R., Link-Gelles, R., Schaffner, W., et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 15 (2015), 301–309.
40. 40 Bonten, M.J., Huijts, S.M., Bolkenbaas, M., et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 372 (2015), 1114–1125.
41. 41 Centers for Disease Control and Prevention, Tetanus surveillance-United States, 2001-2008. MMWR Morb Mortal Wkly Rep 60 (2011), 365–369.
42. 42 McQuillan, G.M., Kruszon-Moran, D., Deforest, A., et al. Serologic immunity to diphtheria and tetanus in the United States. Ann Intern Med 136 (2002), 660–666.
43. 43 Centers for Disease Control and Prevention. Pertussis (whooping cough) surveillance and reporting. Available at: http://www.cdc.gov/pertussis/surv-reporting.html. Accessed October 19, 2015.
44. 44 Skoff, T.H., Kenyon, C., Cocoros, N., et al. Sources of infant pertussis infections in the United States. Pediatrics 136 (2015), 635–641.
45. 45 Grizas, A.P., Camenga, D., Vázquez, M., Cocooning: a concept to protect young children from infectious diseases. Curr Opin Pediatr 24 (2012), 92–97.
46. 46 Centers for Disease Control and Prevention. Combined Tdap vaccine. 2014. Available at: http://www.cdc.gov/vaccines/vpd-vac/combo-vaccines/DTaP-Td-DT/tdap.htm. Accessed October 19, 2015.